Showing 3441-3450 of 20414 results for "".
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
https://reachmd.com/programs/cme/the-current-therapeutic-landscape-in-unresectable-stage-iii-nsclc/36148/Reimagine lung cancer care—discover how new and emerging therapies are reshaping the treatment of SCLC and NSCLCFrom Silent Killer to Treatable Disease: Improved Detection Methods for Ovarian Cancer
https://reachmd.com/programs/clinicians-roundtable/from-silent-killer-treatable-disease-improved-detection-methods-ovarian-cancer/7929/From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancTelehealth in MS Care: Addressing the Potential for Improvement and Concerns
https://reachmd.com/programs/neurofrontiers/telehealth-in-ms-care-addressing-the-potential-for-improvement-and-concerns/18039/Tune in as we discuss ways to leverage technology to advance access to care for multiple sclerosis patients.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://reachmd.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.Prolonged Anticoagulation After Primary PCI for STEMI Does Not Reduce Ischemic Events
https://reachmd.com/cme/pace-cme/prolonged-anticoagulation-after-primary-pci-for-stemi-does-not-reduce-ischemic-events/16001/Here's a recap of the RIGHT trial, as presented at the 2023 ESC Congress.The Most Important Meal of the Day
https://reachmd.com/programs/what-your-patients-are-talking-about/the-most-important-meal-of-the-day/7149/Skipping breakfast could mean a higher heart disease risk; Dr. McDonough discusses.Octane Aesthetics Tech Forum: Octane CEO on Innovation, Growth, and What’s Next
https://reachmd.com/conferences/octane-atf-2026/octane-aesthetics-tech-forum-octane-ceo-on-innovation-growth-and-whats-next/54709/Octane CEO Bill Carpou discusses the continued growth of the Aesthetics Tech Forum, key takeaways from the 2026 meeting, and emerging trends in aesthetics technology.Diving into Diverticular Disease: A Look at Evolving Clinical Insights
https://reachmd.com/programs/gi-insights/diving-into-diverticular-disease-a-look-at-evolving-clinical-insights/13731/What has changed in the treatment paradigm for diverticular disease? Here’s what you need to know about emerging therapies.Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM
https://reachmd.com/programs/acc-action-center/cardiac-myosin-inhibitor-reduces-need-for-septal-reduction-therapy-in-obstructive-hcm/13779/Explore the design and results of the VALOR-HCM trial with this recap of a session from ACC 2022.Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM
https://reachmd.com/programs/acc-action-center/cardiac-myosin-inhibitor-sustainably-reduces-lvot-gradient-in-hcm/13775/Find out what the EXPLORER-HCM study could mean for patients with hypertrophic cardiomyopathy with this recap of a session from ACC 2022.